Advertisement

Medical Needs in the Treatment of Psychotic Disorders

  • F. Markus LewekeEmail author
  • Thorsten M. Odorfer
  • J. Malte Bumb
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 212)

Abstract

Schizophrenia and psychotic disorders represent psychiatric disease patterns characterized by remarkable impairment arising from alterations in cognition, perception, and mood. Although these severe illnesses have been known for more than 100 years, psychopharmacological treatment of their characteristically broad spectrum of symptoms as well as patients’ quality of life, compliance, and time to relapse still remain a challenge in everyday clinical practice. In the following, we will provide a brief synopsis of first-generation antipsychotics (FGAs) followed by a detailed description of current second-generation antipsychotics (SGAs) along with their effects and side effects to evaluate unmet needs in the treatment of schizophrenia and psychotic disorders.

Overall, drug profiles differ concerning their efficacy, associated side effects, cost, and mechanism of action. Thus, a shared decision-making process taking all these factors into account is necessary to develop an effective treatment based on currently approved compounds. To date, however, the spectrum of options is limited and only serves a limited proportion of patients. In addition, certain symptoms do not respond well to currently available strategies or respond only at the price of considerable side effects leading to reduced compliance and adherence in a substantial number of cases.

Unmet needs in the field of antipsychotic treatment are found in a wide range of areas starting from efficacy, safety and tolerability, compliance and adherence, and continuing to stage-dependent and more personalized approaches.

Keywords

Medical needs First- and second-generation antipsychotics Schizophrenia Compliance Patient adherence Quality of life Side effects 

Notes

Acknowledgements

We gratefully acknowledge the helpful discussion and input from Dr. A. Meyer-Lindenberg during the preparation of this manuscript. We would like to thank Ms. W. VanSyckel for carefully editing this article.

References

  1. Adams CE, Awad G, Rathbone J, Thornley B (2007) Chlorpromazine versus placebo for schizophrenia Cochrane Database Syst Rev (2):CD000284Google Scholar
  2. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M (2010) Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull 43:45–66PubMedGoogle Scholar
  3. Arif SA, Mitchell MM (2011) Iloperidone: a new drug for the treatment of schizophrenia. AJHP 68:301–308PubMedGoogle Scholar
  4. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X (2008) Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2:67–77PubMedCrossRefGoogle Scholar
  5. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633Google Scholar
  6. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B (2003) Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 60:99–100PubMedCrossRefGoogle Scholar
  7. Ban TA (2007) Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 3:495–500PubMedGoogle Scholar
  8. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517–2530PubMedCrossRefGoogle Scholar
  9. Beaumont G (2000) Antipsychotics–the future of schizophrenia treatment. Curr Med Res Opin 16:37–42PubMedGoogle Scholar
  10. Bebbington PE (1995) The content and context of compliance. Int Clin Psychopharmacol 9(Suppl 5):41–50PubMedCrossRefGoogle Scholar
  11. Bespalov A, Klein C, Behl B, Gross G, Schoemaker H (2012) Development of disease-modifying treatment of schizophrenia. In: Geyer MA, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, HeidelbergCrossRefGoogle Scholar
  12. Beitinger R, Lin J, Kissling W, Leucht S (2008) Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry 32:1643–1651PubMedCrossRefGoogle Scholar
  13. Bostwick JR, Guthrie SK, Ellingrod VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29:64–73PubMedCrossRefGoogle Scholar
  14. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162:1879–1887PubMedCrossRefGoogle Scholar
  15. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A, Cazorla P (2012) Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 32:36–45PubMedCrossRefGoogle Scholar
  16. Burlon M (2007) Pharmakotherapy der Schizophrenie—“State of the art”. NeuroTransmitter 5:59–70Google Scholar
  17. Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121–124PubMedCrossRefGoogle Scholar
  18. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG (2007) Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 68:29–36PubMedCrossRefGoogle Scholar
  19. Citrome L (2010) Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 64:707–718PubMedCrossRefGoogle Scholar
  20. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ (2011) Grand challenges in global mental health. Nature 475:27–30PubMedCrossRefGoogle Scholar
  21. Copolov DL, Link CG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 30:95–105PubMedCrossRefGoogle Scholar
  22. Correll CU (2011) What are we looking for in new antipsychotics? J Clin Psychiatry 72(Suppl 1):9–13PubMedCrossRefGoogle Scholar
  23. Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425PubMedCrossRefGoogle Scholar
  24. Costa AM, Lima MS, Mari Jde J (2006) A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo medical journal = Revista paulista de medicina 124:291–297PubMedGoogle Scholar
  25. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491–505CrossRefGoogle Scholar
  26. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126PubMedCrossRefGoogle Scholar
  27. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103–108PubMedCrossRefGoogle Scholar
  28. Dollfus S, Olivier V, Chabot B, Deal C, Perrin E (2005) Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 78:157–159PubMedCrossRefGoogle Scholar
  29. Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (1):CD000059Google Scholar
  30. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23:637–651PubMedCrossRefGoogle Scholar
  31. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738–1749PubMedCrossRefGoogle Scholar
  32. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60:81–85PubMedCrossRefGoogle Scholar
  33. Gross G, Drescher K (2012) The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
  34. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178:506–517PubMedCrossRefGoogle Scholar
  35. Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) Metabolic consequences of antipsychotic therapy – preclinical and clinical perspectives on diabetes, diabetic ketoacidosis and obesity. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
  36. Heck AH, Haffmans PM, de Groot IW, Hoencamp E (2000) Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res 46:97–105PubMedCrossRefGoogle Scholar
  37. Hellewell JS (2002) Quetiapine: a well-tolerated and effective atypical antipsychotic. Hosp Med 63:600–603PubMedGoogle Scholar
  38. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194PubMedCrossRefGoogle Scholar
  39. Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
  40. Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM (2009) A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34:433–442PubMedGoogle Scholar
  41. Hori H, Noguchi H, Hashimoto R, Nakabayashi T, Omori M, Takahashi S, Tsukue R, Anami K, Hirabayashi N, Harada S, Saitoh O, Iwase M, Kajimoto O, Takeda M, Okabe S, Kunugi H (2006) Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 86:138–146PubMedCrossRefGoogle Scholar
  42. Insel TR (2010) Rethinking schizophrenia. Nature 468:187–193PubMedCrossRefGoogle Scholar
  43. Jayaram MB, Hosalli PM, Stroup TS (2007) Risperidone versus olanzapine for treatment of schizophrenia. Schizophr Bull 33:1274–1276PubMedCrossRefGoogle Scholar
  44. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087PubMedCrossRefGoogle Scholar
  45. Joy CB, Adams CE, Lawrie SM (2006) Halopridol versus placebo for schizophrenia. Cochrane Database Syst Rev 18(4):CD003082Google Scholar
  46. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12:934–945PubMedCrossRefGoogle Scholar
  47. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097PubMedCrossRefGoogle Scholar
  48. Kane JM, Correll CU (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115–1124PubMedCrossRefGoogle Scholar
  49. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J (2011) A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 72:349–355PubMedCrossRefGoogle Scholar
  50. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173–184PubMedCrossRefGoogle Scholar
  51. Kern RS, Green MF, Nuechterlein KH, Deng BH (2004) NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res 72:11–19PubMedCrossRefGoogle Scholar
  52. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: (4) CD006569Google Scholar
  53. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010a) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (3):CD006654Google Scholar
  54. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010b) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (1):CD006625Google Scholar
  55. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK (2005) Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry J Assoc Eur Psychiatrist 20:409–415CrossRefGoogle Scholar
  56. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892–909PubMedCrossRefGoogle Scholar
  57. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51–68PubMedCrossRefGoogle Scholar
  58. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152–163PubMedCrossRefGoogle Scholar
  59. Leucht S, Heres S, Kissling W, Davis JM (2011) Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14:269–284PubMedCrossRefGoogle Scholar
  60. Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012a) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200:97–106PubMedCrossRefGoogle Scholar
  61. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012b) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071PubMedCrossRefGoogle Scholar
  62. Lieberman J, Pollack S, Lesser M, Kane J (1988) Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 8:254–260PubMedGoogle Scholar
  63. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRefGoogle Scholar
  64. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA (2009) Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry 10:710–718PubMedCrossRefGoogle Scholar
  65. Luft B, Taylor D (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 7:1739–1748PubMedCrossRefGoogle Scholar
  66. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Hansen K, Toumi M (2007) Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 191:30–37PubMedCrossRefGoogle Scholar
  67. McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010) Drug class review: atypical antipsychotic drugs: Final Update 3 Report [Internet] Drug Class Reviews, Portland (OR)Google Scholar
  68. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610PubMedCrossRefGoogle Scholar
  69. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56PubMedGoogle Scholar
  70. Meltzer HY, Massey BW (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11:59–67PubMedCrossRefGoogle Scholar
  71. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82–91PubMedCrossRefGoogle Scholar
  72. Meyer-Lindenberg A (2010) From maps to mechanisms through neuroimaging of schizophrenia. Nature 468:194–202PubMedCrossRefGoogle Scholar
  73. Möller HJ (2004) Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:108–116PubMedCrossRefGoogle Scholar
  74. Mortimer A, Martin S, Loo H, Peuskens J (2004) A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 19:63–69PubMedCrossRefGoogle Scholar
  75. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT (2007) Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 22:445–454PubMedCrossRefGoogle Scholar
  76. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111:106–115PubMedCrossRefGoogle Scholar
  77. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMedCrossRefGoogle Scholar
  78. Peluso MJ, Lewis SW, Barnes TRE, Jones PB (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200:387–392PubMedCrossRefGoogle Scholar
  79. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166:712–726, discussion 727–33PubMedCrossRefGoogle Scholar
  80. Peuskens J, Link CG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265–273PubMedCrossRefGoogle Scholar
  81. Peuskens J, De Hert M, Mortimer A (2007) Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 22:145–152PubMedCrossRefGoogle Scholar
  82. Potkin SG (2011) Asenapine: a clinical overview. J Clin Psychiatry 72(Suppl 1):14–18PubMedCrossRefGoogle Scholar
  83. Potvin S, Stip E, Lipp O, Elie R, Mancini-Marie A, Demers MF, Roy MA, Bouchard RH, Gendron A (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 22:1277–1285PubMedCrossRefGoogle Scholar
  84. Puschner B, Born A, Giessler A, Helm H, Becker T, Angermeyer MC (2005) Effects of interventions to improve compliance with antipsychotic medication in people suffering from schizophrenia-results of recent reviews. Psychiatr Prax 32:62–67PubMedCrossRefGoogle Scholar
  85. Rattehalli RD, Jayaram MB, Smith M (2010) Risperidone versus placebo for schizophrenia. Schizophr Bull 36:448–449PubMedCrossRefGoogle Scholar
  86. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 161:473–479PubMedCrossRefGoogle Scholar
  87. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163:2096–2102PubMedCrossRefGoogle Scholar
  88. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D (2000) Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 61:382–386PubMedCrossRefGoogle Scholar
  89. Ruhrmann S, Klosterkotter J, Bodatsch M, Bechdolf A, Schimmelmann BG, Nikolaides A, Hilboll D, Schultze-Lutter F (2012) Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 18:550–557PubMedCrossRefGoogle Scholar
  90. Sacchetti E, Valsecchi P (2003) Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 18:357–359PubMedCrossRefGoogle Scholar
  91. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131PubMedCrossRefGoogle Scholar
  92. Srisurapanont M, Maneeton B, Maneeton N (2004) Quetiapine for schizophrenia. Cochrane Database Syst Rev (2):CD000967Google Scholar
  93. Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11:313–327PubMedCrossRefGoogle Scholar
  94. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622PubMedCrossRefGoogle Scholar
  95. Tarsy D, Lungu C, Baldessarini RJ (2011) Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100:601–616PubMedCrossRefGoogle Scholar
  96. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627PubMedCrossRefGoogle Scholar
  97. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52–63PubMedCrossRefGoogle Scholar
  98. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407–418PubMedCrossRefGoogle Scholar
  99. Umbricht D, Kane JM (1995) Risperidone: efficacy and safety. Schizophr Bull 21:593–606PubMedGoogle Scholar
  100. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM (2006) Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 113:91–95PubMedCrossRefGoogle Scholar
  101. Weiden PJ (2007) EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 13:13–24PubMedCrossRefGoogle Scholar
  102. Weinmann S, Read J, Aderhold V (2009) Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113:1–11PubMedCrossRefGoogle Scholar
  103. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA (2006) Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 67:1093–1103PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • F. Markus Leweke
    • 1
    Email author
  • Thorsten M. Odorfer
    • 1
  • J. Malte Bumb
    • 1
  1. 1.Department of Psychiatry and Psychotherapy, Central Institute of Mental HealthUniversity of Heidelberg, J5MannheimGermany

Personalised recommendations